Malaria in pregnancy: efficacy of a low dose of mefloquine in an area holoendemic for multi-drug resistant<i>Plasmodium falciparum</i>

Okeyeh, J. N.; Lege-Oguntoye, L.; Emembolu, J.O.; Agbo, Martin Chinonye

doi:10.1080/00034983.1996.11813051

Cited by 6 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main complaints of recipients were nausea and itching. In a similar, non-comparative study undertaken in Nigeria, where a much lower MQ dose (12.5 mg/kg) was used, only minimal side effects were reported [47]. Two additional, small, randomized but not blinded P. falciparum treatment studies have been published [48,49].…”

Section: Resultsmentioning

confidence: 99%

Mefloquine safety and tolerability in pregnancy: a systematic literature review

González

Hellgren

Greenwood

et al. 2014

Malar J

View full text Add to dashboard Cite

Background: Control of malaria in pregnant women is still a major challenge as it constitutes an important cause of maternal and neonatal mortality. Mefloquine (MQ) has been used for malaria chemoprophylaxis in non-immune travellers for several decades and it constitutes a potential candidate for intermittent preventive treatment in pregnant women (IPTp). Methods: The safety of MQ, including its safety in pregnancy, is controversial and a continuing subject of debate. Published studies which evaluated the use of MQ for malaria prevention or treatment in pregnant women and which reported data on drug tolerability and/or pregnancy outcomes have been reviewed systematically.

show abstract

Section: Resultsmentioning

confidence: 99%

Mefloquine safety and tolerability in pregnancy: a systematic literature review

González

Hellgren

Greenwood

et al. 2014

Malar J

View full text Add to dashboard Cite

show abstract

“…Mefloquine has been used alone for prophylaxis in the pre-conception period and in all trimesters of pregnancy[4,37-39,41,60] and used for the treatment of chloroquine and multidrug-resistant falciparum malaria in pregnancy, both as monotherapy[4,61-63] and in combination with other antimalarials, particularly artemisinins [64-66]. …”

Section: Resultsmentioning

confidence: 99%

“…A low dose mefloquine treatment regimen (12.5 mg/kg as single oral dose) given to 33 women in the second or third trimester in Zaria, Nigeria was well tolerated, safe and effective with no adverse maternal or foetal outcomes reported[61]. In a large prospective study in Malawi, 4,187 women who presented to an antenatal clinic with parasitaemia in the second or third trimester were randomly assigned to 1 of 4 treatment and/or prophylaxis regimens containing chloroquine or mefloquine[4].…”

Section: Resultsmentioning

confidence: 99%

Intermittent preventive treatment for malaria in pregnancy in Africa: What's new, what's needed?

Vallely

Changalucha

et al. 2007

Malar J

View full text Add to dashboard Cite

Falciparum malaria is an important cause of maternal, perinatal and neonatal morbidity in high transmission settings in Sub-Saharan Africa. Intermittent preventive treatment with sulphadoxinepyrimethamine (SP-IPT) has proven efficacious in reducing the burden of pregnancy-associated malaria but increasing levels of parasite resistance mean that the benefits of national SP-IPT programmes may soon be seriously undermined in much of the region. Hence, there is an urgent need to develop alternative drug regimens for IPT in pregnancy. This paper reviews published safety and efficacy data on various antimalarials and proposes several candidate combination regimens for assessment in phase II/III clinical trials.

show abstract

Responses of multidrug‐resistant Plasmodium falciparum parasites to mefloquine in Nigerian children

Lege-Oguntoye

et al. 1997

Tropical Med Int Health

Self Cite

View full text Add to dashboard Cite

SummaryThirty-three children aged 6 months to 7 years from an area with multidrug-resistant Plasmodium falciparum strains were treated with 25 mg/kg body weight of mefloquine hase as a single oral dose. They were followed-up using the modified 28-day W H O extended field test. The parasite isolates from these patients were cultured in vitro with different concentrations of mefloquine. All children were parasite-negative by day 4, and 3 T remained so throughout the period of observation. Two patients who were parasitaemic o n days 1 6 and 2 8 were successfully treated with a sulphadoxine/pyrimethamine combination. Parasitological and clinical responses were well correlated. The mean parasite clearance time was 65 i 50.2 hours. A mefloquine concentration of 64 pmol/well inhibited schizont growth and the EC,, and EC,, were 5.5 and 54 pmol/well (1.1 and 10.8 pmol/l blood) respectively. This indicates reduced parasite susceptibility to the drug in vitro.keywords mefloquine, resistant Plasmodium falciparum strains

show abstract

Malaria in pregnancy: efficacy of a low dose of mefloquine in an area holoendemic for multi-drug resistantPlasmodium falciparum

Cited by 6 publications

References 8 publications

Mefloquine safety and tolerability in pregnancy: a systematic literature review

Mefloquine safety and tolerability in pregnancy: a systematic literature review

Intermittent preventive treatment for malaria in pregnancy in Africa: What's new, what's needed?

Responses of multidrug‐resistant Plasmodium falciparum parasites to mefloquine in Nigerian children

Contact Info

Product

Resources

About